Single Blog Title

This is a single blog caption

Delhi Declaration on Non-Communicable Diseases

19 August 2016, Delhi, India,

Foreword

For the first time in the modern history of India, non-communicable diseases (NCDs) have surpassed communicable diseases as the most common cause of morbidity and premature mortality.

Cardiovascular diseases, cancers, chronic respiratory diseases, diabetes and other NCDs accounting for 60% of all deaths in India, are the leading cause of death – ahead of injuries and communicable, maternal, prenatal, and nutritional conditions. Furthermore, NCDs account for about 40% of all hospital stays and roughly 35% of all recorded outpatient visits.[1]

While much progress has been made in recent years to address the challenges and growing burden of NCDs, there is more work ahead. Under the leadership of the Ministry of Health and Family Welfare, Ministry of Chemicals & Fertilizers and in collaboration with relevant government authorities, medical practitioners and other distinguished professionals, the Organisation of Pharmaceutical Producers of India (OPPI) puts forth this document, as intent, to take action against NCDs.

The objective of the Delhi Declaration on Non-Communicable Diseases is to achieve the SDG 3.4 goals and direct actions to combat NCDs in India.  This is a pledge to bring innovative and sustainable solutions that reduce the social, economic and medical burdens of NCDs on Indian patients. The proposed actions are those that are manageable, sustainable, and serve as an inspiration across India.

Together we should join forces to increase Awareness, build Capacity and elevate Treatment.

Together, we must ACT on NCDs.

The partners and stakeholders agree on working together to address the key deliverables:

Key Deliverables from the 5th Healthcare access summit 2016

Awareness

Most NCDs typically do not show any early symptoms and remain undiagnosed and therefore undetected. Patients complain of complications that are diagnosed at a very late stage, leading to poor patient outcomes. There is strong evidence that early detection and treatment of NCDs has a positive impact on disease progression, leading to fewer complications and better quality of life with increased life expectancy.

  • Strengthen policy to include preventive care and ensure healthy lives across all age-groups
    • Enhance multi-sectoral, multi-stakeholder approach and work together to raise awareness on common risk factors affecting the entire community. Conduct mass media campaigns to increase awareness on early diagnosis and primordial prevention of NCDs.
    • Include awareness and prevention on NCDs as an essential part of school curriculum in order to make a necessary shift in social behavior and begin instilling ‘healthy living’ as a norm, at a very young age.
    • Promote physical activity and healthy eating through “role models”
    • Adopt a pre-emptive approach in the fight against NCDs as it slows or stop the progression of diseases. It is cost-effective and achievable as it targets only those who are at pre-disease stage.

Capacity building

The NCD burden will remain unresolved until access to affordable treatment and counselling is made a priority. Inadequate access to appropriate medication, insufficient knowledge about complications and inability to manage long- term care are impediments in containing this disease burden. NCD management through ‘optimal are’ needs to include

  • Training of healthcare professionals at primary, secondary and tertiary levels on integrated Non Communicable Diseases management.
    • Public Private Partnerships for training, medical education, diagnostic equipment, and preventive care delivery requirements, to promote efficient use of resources.
    • Partnerships between Government and NGOs, civil society and patient groups in order to promote capacity building at all levels.
    • Dedicated module on NCDs to be included in MBBS, Nursing and pharmacy curriculum to strengthen both the effectiveness of the health system in managing NCDs.

Treatment

A patient-centric approach to improve the NCDs pathway will keep people healthy and delay complications and co-morbidities for as long as possible. This will require a coordinated approach involving primary, secondary, tertiary care and the social sector, with the individual at the centre.

  • Create a patient-friendly healthcare ecosystem for Non Communicable Diseases management, including primary, secondary and tertiary preventive strategies.
    • Optimal utilization of existing healthcare infrastructure for basic treatment & management of NCDs at the sub centers, community health centers, district hospitals and tertiary level institutes – for improved access to care for NCDS.
    • Keep the patient at the center of care and focus on the community for long term management of disease
    • Encourage further investment to scale up the ‘NCD Clinic’ model, a GoI initiative, at the primary healthcare level as the treatment paradigm of NCDs is fundamentally different from acute diseases.
    • Include private sector for accountability and timely healthcare delivery

The Pharmaceutical companies operating in India will continue to provide their complete support and cooperation as partners in creating awareness and capability building as well as expanding reach of treatment options.

About the Delhi Declaration on Non-Communicable Diseases

The Delhi Declaration on Non-Communicable Diseases is inspired by the World Health Organisation’s Global Action Plan for Prevention and Control of Non-communicable Diseases 2013-2020 & The National Action Plan & Monitoring Framework for Prevention & Control of NCDs document of the Government of India.

The Delhi Declaration on Non-Communicable Diseases is the joint effort and intent of multiple stakeholders, including the hosts, partners, endorsers, supporters, speakers, and participants at the OPPI Fifth Healthcare Access Summit.

 

9.00  AM – 9.30 AM Registration & Tea
Inaugural Session
09.30 AM – 09.35 AM Welcome & Opening Remarks Kanchana TK, Director General, OPPI
09.35  AM – 09.45 AM Setting the Context Sudarshan Jain, Vice President, OPPI &Chairman, OPPI Access and Affordability Work Group & Managing Director, Healthcare Solutions, Abbott Healthcare
09.45 AM  – 10.00 AM Inaugural Address Dr Shailesh Ayyangar, President, OPPI &Managing Director, India & Vice President, South Asia, Sanofi
10:00 AM – 10:30 AM Keynote Address Lars Rebien Sorensen, President and Chief Executive Officer, Novo Nordisk A/S
10:30 AM – 10:40 AM Address by Guest of Honor Dr Arun Panda, Additional Secretary, Ministry of Health
10:40 AM – 10:50 AM Special Address & Pledge Sachin Tendulkar Changing Diabetes® Brand Ambassador for Novo Nordisk
10:50 AM – 11:00 AM Address by Guest of Honor Dr Jagdish Prasad, Director General of Health Services (DGHS)
11:00 AM – 11.05 AM Release of Publication KPMG – OPPI Report on Healthcare Access Initiatives
11:05 AM – 11:10 AM Announcement of Winners of the Awards:· OPPI Healthcare Access Award 2016OPPI Healthcare Access Award on NCDOPPI Award for improving Access to Diabetes Care Sharad Tyagi, Vice President, OPPI & Chairman, OPPI Compliance & Governance Work Group &Managing Director, Boehringer Ingelheim
11.10 AM – 11.30 AM Address by Chief Guest Dr Jitendra Singh, Hon’ble Minister of State in the Prime Minister’s Office (PMO)
11.30 AM  – 11.45 Noon Break
11:45 PM – 12.15 PM Address by Award Winners OPPI Healthcare Access Award 2016·    OPPI Healthcare Access Award on NCDsOPPI Award for improving Access to Diabetes Care
Special Session : NCDs  – Issues, Challenges & the way forward       Chair  : Ranjit Shahani, Novartis
12:15 PM – 12:30 PM Diabetes Dr Shaukat Sadikot, President IDF
12:30 PM  – 12.45 PM Cardio / Stroke Dr H K Chopra, Chief Cardiologist, Moolchand Medicity
12.45 PM  – 01:00 PM Cancer Dr Purvish Parikh, Asian Cancer Institute
01.00 PM – 02.00 PM Lunch
Special Session :
02:00 PM – 02:05 PM Introduction to the Panel Discussion: ACT on NCDs     Dr Ashok Kumar Das, Institute of Medical Sciences, Pondicherry                                                      
Plenary Session 1 Panel Discussion: ACT on NCDs                                   
Panel Discussion 102:05 PM – 02:50 PM (Awareness) Scaling up NCDs awareness and diagnosis in India – National guidelines for managing NCDs at primary careConvergence with ongoing public health programs for awareness and screeningNational guidelines for population based screeningExploring ways to utilize  social media for preventionChallenges and opportunities to reduce NCD risk factorsInnovative approaches towards awareness, prevention and  reduction of NCDs risk factors Chairperson: Annaswamy Vaidheesh, GSK Panel:-Dr Ravi Mehrotra, National Institute of  Cancer Prevention & ResearchDr Ken Thorpe, PFCD

Dr Sadhana Bhagwat, WHO

Dr S D Gupta, IIHMR

Amit Mookim, IMS

 

Panel Discussion 202:50 PM – 03:35 PM (Capacity Building) Achieving India targets for NCD-related risk factors through capacity building – Building support and capacity for implementation to reduce NCD risk factorsStrengthening and orienting current health systems to address NCDs at grassroots levelStrengthening healthcare workforce capacity to manage NCDs in primary careBuilding capacity of primary care workforce towards managing NCDBest practices towards building capacity for NCDs care Chairperson: K.G. Ananthakrishnan, MSDPanel:-Rajendra Gupta, ConsultantDr Ratna Devi, Indian Alliance of Patient Groups

Dr Satish Kumar, NHSRC

Venkat Changavalli, Advisor to Govt of UP for Health

Dr D. Prabhakaran, PHFI

 

03:35 PM – 03:55 PM Break
Panel Discussion 303:55 PM – 04:40 PM (Treatment) Development and implementation of national treatment guidelines and policies for prevention and control of NCDs·       Strengthening national capacity, leadership, Governance and partnership towards “Standard National Treatment Guidelines” for NCDsAccess to essential NCDs medicines and technologyMonitoring and evaluation of trends of NCDs through researchInsurance: Enabler to enhance the NCD care access Chairperson: Sanjiv Navangul, Johnson & JohnsonPanel:-Dr Y K Gupta, AIIMSS.V. Veeramani, IDMA

Bejon Misra, Patient Safety & Access Initiative of India Foundation

Gagan Bhalla, Apollo Sugar

Dr Ashoke Bhattcharjya, Johnson & Johnson

Plenary Session 2        Delhi Declaration: “ACT on NCDs”                                          
04:40 PM – 04:55 PM Delhi Declaration “ACT on NCDs” Prof Shashank Joshi (Padmashree Awardee)
04:55 PM – 05:05 PM Summing-up & Vote of Thanks Melvin D’Souza, Co-Chairman, OPPI Access and Affordability Work Group &
VP & GM, Novo Nordisk India Private Limited

 

[1] http://www.who.int/features/2015/ncd-india/en/

Leave a Reply